Auditing PSUR Submissions and Tracking Compliance in Pharmacovigilance

Periodic Safety Update Reports (PSURs) are vital components of post-marketing pharmacovigilance. These reports not only monitor the safety profile of authorized medicines but also reflect the sponsor’s commitment to regulatory compliance. To ensure continuous adherence to regulatory expectations, organizations must audit their PSUR processes and track compliance meticulously. This tutorial offers guidance on auditing PSUR submissions and establishing robust compliance tracking systems to maintain global standards.

Why PSUR Auditing Is Critical

Auditing PSUR processes allows organizations to:

• Verify completeness and accuracy of safety data submitted
• Evaluate adherence to regulatory timelines
• Identify systemic gaps or process inefficiencies
• Prepare for inspections by agencies like the EMA and CDSCO (India)
• Support continuous quality improvement

A well-executed audit program demonstrates that pharmacovigilance systems are not only operational but also effective in fulfilling post-marketing obligations.

Key Areas to Audit in PSUR Lifecycle

Organizations should conduct regular audits of the entire PSUR lifecycle, from data collection to submission and archiving. Key areas include:

1. Signal management: Are identified signals evaluated and documented properly in Section 7?
2. Benefit-risk integration: Is there consistency in how safety and benefit data are analyzed and presented?
3. Data sources: Are all required sources—clinical, spontaneous, literature—captured?
4. Submission timeliness: Were reports submitted according to regulatory timelines?
5. Format and structure: Is the PSUR aligned with ICH E2C(R2) and local expectations?

Refer to Pharma SOP templates to benchmark your audit criteria.

Building an Effective PSUR Audit Checklist

An audit checklist helps ensure consistency and thoroughness. Sample items include:

• Does the PSUR include all required sections as per ICH guidance?
• Have all applicable products and markets been included in the submission?
• Are signal evaluations supported by sufficient data and justification?
• Is the benefit-risk section internally consistent with safety findings?
• Are timelines tracked and documented with justification for delays, if any?
• Was QA review documented and archived?

Customizing your checklist for specific regional requirements is advised. For instance, USFDA submissions may be integrated into PADERs, while TGA may demand region-specific addenda.

Tracking PSUR Compliance: Metrics and Tools

Compliance tracking involves monitoring key performance indicators (KPIs) related to PSUR submissions. Common metrics include:

• On-time submission rate (%)
• Number of audit findings per report
• Signal evaluation turnaround time
• Review cycle duration from data lock point (DLP) to final approval
• CAPA (Corrective and Preventive Actions) closure timelines

Use of digital dashboards and compliance management systems helps in visualizing these metrics across products and geographies. Validation of these systems is recommended under computer system validation protocols.

Implementing a PSUR Compliance Tracker

A PSUR tracker can be maintained in Excel or in a pharmacovigilance tool. Essential fields include:

1. Product name and active substance
2. Country or region of submission
3. DLP and reporting frequency (e.g., biannual, annual)
4. Submission due date and actual submission date
5. Health authority acknowledgment or feedback
6. CAPAs and responsible owner

This tracker should be updated in real-time and shared with cross-functional stakeholders including regulatory affairs and QA.

Common Audit Findings in PSURs

Some frequently observed audit findings include:

• Omissions in cumulative safety data
• Incorrect DLPs leading to misaligned timelines
• Incomplete signal assessment narratives
• Unjustified deviations from submission SOPs
• Delayed CAPA implementation

These issues often stem from unclear ownership, inadequate training, or lack of harmonized templates. Address these through documented training programs and standardized templates sourced from GMP SOP guidelines.

Preparing for Regulatory Inspections

During inspections, agencies may request:

• Full PSUR dossiers and revision history
• Evidence of signal evaluation and benefit-risk reasoning
• Audit reports and CAPA records
• Compliance metrics dashboards
• Submission confirmations or acknowledgment letters

Ensure all these documents are stored securely and readily accessible. Many companies use stability data systems that integrate with PSUR generation workflows.

Best Practices for PSUR Audit Readiness

• Schedule periodic internal audits annually
• Include cross-functional auditors to widen perspective
• Automate timeline tracking and alerts
• Link PSUR reviews to risk management plans (RMPs)
• Use mock inspections to assess readiness

Conclusion

Auditing PSUR submissions and tracking compliance are non-negotiable aspects of a mature pharmacovigilance system. With increasing scrutiny from global health authorities, pharmaceutical companies must adopt proactive strategies to ensure their PSUR processes are transparent, robust, and inspection-ready. Implementing audit checklists, using trackers, and deploying validation-backed systems ensures compliance—and more importantly—enhances patient safety and product lifecycle integrity.

Common Mistakes in PSUR Compilation and How to Avoid Them

Periodic Safety Update Reports (PSURs) play a vital role in post-marketing surveillance of pharmaceutical products. These reports help regulatory bodies monitor the benefit-risk profile of drugs and ensure patient safety. However, compiling a PSUR is a complex process that can be vulnerable to several mistakes if not properly managed. This guide identifies common PSUR compilation errors and outlines practical strategies for prevention, improving compliance and audit readiness across global pharmacovigilance operations.

1. Inconsistent or Incomplete Signal Evaluations

Signal evaluation is one of the most critical sections of the PSUR. A frequent mistake is presenting vague, incomplete, or unsubstantiated signal narratives. Sponsors may list adverse events without proper evaluation of frequency, severity, causality, or comparison with historical data.

Best practices include:

• Using structured formats for signal templates
• Referencing data from stability studies and real-world safety databases
• Including statistical support where feasible
• Cross-referencing with the cumulative summary tables

2. Data Lock Point (DLP) and Timeline Confusion

Another common issue is confusion around the Data Lock Point (DLP), leading to discrepancies in the period covered by the report. Late identification of the DLP can compress timelines, resulting in rushed reviews and errors.

To avoid this:

• Establish a PSUR calendar synced with regional requirements
• Send DLP reminders 30-60 days in advance
• Use automated alerts within validated pharmacovigilance systems

3. Discrepancies in Benefit-Risk Assessments

Many PSURs contain inconsistent or generic benefit-risk analyses that do not align with the safety findings or signal evaluation sections. This undermines the credibility of the report and can raise red flags during audits or inspections.

Ensure that:

• All significant safety issues discussed in Section 7 are reflected in Section 8
• Benefit-risk is customized for product use patterns and patient populations
• The impact of labeling or RMP updates is transparently integrated

4. Poor Formatting and Non-Compliance with ICH Structure

Incorrect formatting, missing headers, or inconsistent document structures are among the most frequent PSUR issues flagged during GMP compliance audits. Agencies such as the EMA and USFDA expect strict adherence to the ICH E2C(R2) PBRER format.

Recommendations:

• Use master templates with predefined headers and section numbers
• Conduct peer reviews and formatting audits prior to finalization
• Standardize referencing for tables, annexures, and figures

5. Omissions in Cumulative Data Presentation

Incomplete cumulative tabulations or omission of specific safety events compromise the integrity of PSURs. Errors in sorting, filtering, or merging data from different sources are common contributors.

Prevent this by:

• Maintaining a centralized safety data repository
• Auditing data sources prior to merging
• Performing QA spot-checks on cumulative line listings and tabulations

6. Failure to Integrate Local Regulatory Requirements

While ICH guidelines are global, individual countries like India, Japan, and Brazil have specific PSUR requirements. Submitting a generic PSUR without tailoring it for local regulations may lead to rejections or queries.

To avoid this:

• Maintain a regulatory intelligence matrix by country
• Assign local reviewers for each regional PSUR
• Embed jurisdiction-specific requirements into your Pharma SOPs

7. Lack of Quality Review and Approval Workflow

Often, PSURs are prepared under time pressure and bypass adequate internal review, leading to factual or typographical errors. This is particularly problematic when multiple regions and languages are involved.

Establish:

• Multi-level internal QA review and sign-off
• Version-controlled document tracking
• Documented CAPAs for audit findings

8. Inadequate Justification for Changes or No Changes

PSURs must include explanations for both implemented and non-implemented safety actions. Failure to justify why a signal didn’t lead to a label update or why a previous action was effective is viewed negatively during inspections.

Best practice:

• Include clear rationale for each change or lack thereof
• Use historical PSUR data for trend justification
• Include summary tables of actions since the last DLP

9. Disorganized Annexures and Incomplete Documentation

Missing or mislabeled annexures—like line listings, narratives, or tabulations—can result in rejection or requests for clarification from regulators.

Ensure:

• Every annexure is clearly indexed and referenced
• All required documents are attached in the correct format
• Submit through the appropriate platform (e.g., eCTD)

10. Neglecting Post-Submission Follow-Up

After submission, sponsors must track acknowledgment, queries, and feedback from regulatory authorities. Ignoring or missing post-submission interactions can delay approvals or trigger penalties.

Recommended actions:

• Use a PSUR compliance dashboard to track submission status
• Assign a regulatory affairs liaison for follow-up communications
• Document all agency interactions for inspection readiness

Conclusion

PSUR compilation is a meticulous process that requires coordination, attention to detail, and compliance with evolving global standards. By recognizing and addressing the most common pitfalls—from formatting errors to benefit-risk inconsistencies—organizations can significantly enhance the quality of their PSURs. Leveraging validated systems, compliance-driven workflows, and harmonized SOPs ensures your reports meet regulatory expectations and support patient safety effectively.